Importantly, in vivo administration of AMI-408 to mice transplanted with pretreated MLL-GAS7 leukemia cells significantly extended the survival and reduced disease penetrance compared with the carrier control (p = 0.0341) (Figure 1L), revealing the therapeutic potential of targeting Prmt1 by a small-molecule inhibitor. This evidence concerns the gene KMT2A and leukemia.